Specific Induction of Right Ventricular-Like Cardiomyocytes from Human Pluripotent Stem Cells: Methodology, Findings, and Research Implications

Study Background and Research Question

Cardiovascular disease remains the foremost cause of mortality worldwide, with a growing subset of patients experiencing pathologies predominantly affecting the right ventricle (RV), such as arrhythmogenic right ventricular cardiomyopathy and right heart failure associated with pulmonary arterial hypertension. Despite advances in left ventricular (LV) therapies, treatment and mechanistic understanding of RV-specific diseases have lagged behind, partly due to the lack of robust, chamber-specific in vitro models. Traditional protocols for differentiating human pluripotent stem cells (hPSCs) into cardiomyocytes typically yield populations resembling LV cells, limiting their utility for RV disease modeling. Saito et al. sought to address this gap by developing a method to specifically induce RV-like cardiomyocytes from hPSCs, enabling more precise studies into RV biology and pathology (Saito et al., 2025).

Key Innovation from the Reference Study

The principal innovation reported by Saito et al. is the development of a modified GiWi protocol that enables the specific differentiation of hPSCs into RV-like cardiomyocytes. The canonical GiWi protocol—based on sequential inhibition of GSK3β (to activate Wnt signaling) followed by direct Wnt inhibition—predominantly yields first heart field (FHF)-like progenitors, which in turn generate LV-like cardiomyocytes. By strategically inhibiting endogenous bone morphogenetic protein (BMP) signaling during the mesoderm induction phase, either with insulin or BMP antagonists, the researchers were able to shift the balance of cardiac progenitor populations towards the second heart field (SHF) lineage, promoting RV-like fate. This approach directly addresses the challenge of producing chamber-specific cardiomyocytes for targeted disease research (Saito et al., 2025).

Methods and Experimental Design Insights

The experimental strategy employed by Saito et al. draws upon established stem cell differentiation workflows, with several key modifications:

• Human pluripotent stem cells were differentiated into cardiac lineages using the GiWi protocol (GSK3β inhibition followed by Wnt inhibition).
• During the mesoderm induction phase, insulin or BMP antagonists were introduced to modulate endogenous BMP signaling.
• Cardiac progenitor cells were profiled for FHF (TBX5⁺/NKX2-5⁺) and SHF (TBX5⁻/NKX2-5⁺) marker expression.
• Differentiated cardiomyocytes were characterized for chamber-specific gene expression, contraction rates, Ca²⁺ transients, and morphological features.

The methodological emphasis on early mesodermal signaling reflects the developmental origins of the LV and RV, which arise from FHF and SHF progenitors, respectively. By altering the signaling environment during this critical window, the team was able to direct cell fate toward an RV-like phenotype.

Protocol Parameters

• Assay: Mesoderm induction | Value: BMP antagonism (insulin or specific antagonists) added during mesoderm formation | Applicability: Directed differentiation of hPSCs toward SHF/RV lineage | Rationale: Suppresses FHF marker expression, enhances SHF marker profile | Source: Saito et al., 2025
• Assay: Cardiac progenitor marker profiling | Value: TBX5 and NKX2-5 expression analysis | Applicability: Chamber-specific progenitor identification | Rationale: Distinguishes FHF (LV) and SHF (RV) lineages | Source: Saito et al., 2025
• Assay: Functional cardiomyocyte assays | Value: Spontaneous contraction rate, Ca²⁺ transient measurement | Applicability: Phenotypic confirmation of chamber identity | Rationale: RV-like cells exhibit distinct functional traits | Source: Saito et al., 2025

Core Findings and Why They Matter

The study demonstrates that modulation of BMP signaling during mesoderm induction reliably shifts cardiac progenitor populations from FHF-like to SHF-like, resulting in cardiomyocytes with robust RV-like characteristics. Specifically:

• Control GiWi protocol yielded primarily FHF-like progenitors and LV-like cardiomyocytes.
• Addition of insulin or BMP antagonists suppressed FHF markers and upregulated SHF markers in progenitor cells.
• Resultant cardiomyocytes displayed RV-like gene expression, a higher spontaneous contraction rate, altered Ca²⁺ handling, and larger cell size compared to LV-like controls.

These findings provide the first direct demonstration that chamber-specific cardiomyocyte fate can be controlled in vitro by targeted signaling pathway modulation. The availability of RV-like hPSC-derived cardiomyocytes will facilitate more accurate disease modeling and pharmacological screening for RV disorders, which until now have been hampered by the lack of suitable cell models (Saito et al., 2025).

Comparison with Existing Internal Articles

Recent internal resources have highlighted the utility of tools such as Veratridine, a voltage-gated sodium channel opener, in cardiac and neuroscience research. For example, "Veratridine: A Benchmark Voltage-Gated Sodium Channel Opener" describes the use of this compound to probe sodium channel function and excitability in cardiac and neuronal models. These articles emphasize Veratridine’s role in sodium channel dynamics research and screening assays for sodium channel blockers, which are highly relevant for functional validation of chamber-specific cardiomyocytes (internal article). Saito et al.’s work complements these scenario-driven applications by providing a method to generate RV-like cardiomyocytes, which could be leveraged in combination with sodium channel modulators such as Veratridine for advanced electrophysiological and excitotoxicity studies. Thus, the new protocol from Saito et al. enables the next step in platform development for cardiac disease modeling and drug testing, as previously anticipated in internal scenario-based guidance (internal article).

Limitations and Transferability

While the protocol introduces a robust method for RV-specific cardiomyocyte induction, several limitations warrant consideration:

• The maturity of hPSC-derived cardiomyocytes remains a challenge; in vitro cells exhibit fetal-like phenotypes, which may not fully recapitulate adult RV physiology (Saito et al., 2025).
• Translational applicability to disease modeling or drug screening will require further validation, particularly in the context of complex multicellular or tissue-engineered systems.
• Functional and molecular comparisons to primary human RV tissue are necessary to confirm the fidelity of the induced phenotype.

Nevertheless, the protocol’s reliance on accessible small-molecule modulators and established marker analysis techniques enhances its reproducibility and transferability to other laboratories.

Research Support Resources

For researchers interested in validating sodium channel function or excitability phenotypes in chamber-specific cardiomyocyte populations, reagents such as Veratridine (SKU B7219) are of practical value. As a well-characterized voltage-gated sodium channel opener, Veratridine can be used to probe sodium channel activity, excitotoxicity, and pharmacological responses in both LV- and RV-like hPSC-derived cardiomyocytes (product_spec; workflow_recommendation). For protocol optimization and scenario-driven guidance, recent internal resources provide detailed handling and application notes for integrating Veratridine into sodium channel dynamics research and screening assays for sodium channel blockers (internal article). APExBIO supplies Veratridine as a standardized research compound to support these advanced workflows.